Abstract
Nuclear medicine imaging is key in the initial diagnostic workup and used for staging and restaging. Also it forms basis for planning of therapy targeting somatostatin receptors, either as somatostatin analogues or peptide receptor radionuclide therapy (PRRT). For decades somatostatin receptor scintigraphy has successfully been performed using gamma camera technique and SPECT with the tracer 111In-DTPA-octreotide. Recently, several positron emission tomography (PET) tracers targeting the somatostatin receptors have been introduced. The most commonly used of these are 68Ga-DOTATATE, 68Ga-DOTATOC, and 68Ga-DOTANOC. They all perform superior to SPECT and should replace gamma camera tracers whenever possible. With FDG-PET it is possible to detect a large proportion of the somatostatin receptor-negative cases, and FDG-PET therefore seems to be a valuable addition. Furthermore, FDG-PET has prognostic information that potentially may be used in selection of therapy. With the abovementioned PET tracers available, the need for 123I-MIBG, 18F-DOPA, and 11C-5-HTP may be limited.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kjaer A (2006) Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol 587:277–284
Hamilton SR, Aaltonen LA, World Health Organization (2000) Pathology and genetics. Tumours of the digestive system, WHO classification of tumors. IARC, Lyon
Binderup T, Knigge U, Mellon Mogensen A et al (2008) Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 87:223–232
Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846
Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731
Öberg K, Knigge U, Kwekkeboom D, Perren A (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii124–30
Jamar F, Fiasse R, Leners N, Pauwels S (1995) Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 36:542–549
Raderer M, Kurtaran A, Leimer M et al (2000) Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol 18:1331–1336
Koopmans KP, Neels ON, Kema IP et al (2009) Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 71:199–213
Lu S-J, Gnanasegaran G, Buscombe J, Navalkissoor S (2013) Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun 34:98–107
Bombardieri E, Ambrosini V, Aktolun C et al (2010) 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37:1441–1448
Binderup T, Knigge U, Loft A et al (2010) Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 51:704–712
Gabriel M, Muehllechner P, Decristoforo C et al (2005) 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 49:237–244
Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R et al (2006) 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging 33:1123–1133
Reubi JC, Schär JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282
Antunes P, Ginj M, Zhang H et al (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993
Johnbeck CB, Knigge U, Kjaer A (2014) Somatostatin receptor imaging with PET tracers of neuroendocrine tumors: current status and review of the literature. Future Oncol 10:2259–2277
Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455
Kayani I, Conry BG, Groves AM et al (2009) A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 50:1927–1932
Haug A, Auernhammer CJ, Wängler B et al (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770
Kabasakal L, Demirci E, Ocak M et al (2012) Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39:1271–1277
Wild D, Bomanji JB, Benkert P et al (2013) Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 54:364–372
Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751–1757
Koukouraki S, Strauss LG, Georgoulias V et al (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466
Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626
Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518
Putzer D, Gabriel M, Henninger B et al (2009) Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 50:1214–1221
Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 35:321–328
Ambrosini V, Tomassetti P, Castellucci P et al (2008) Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35:1431–1438
Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, Montini GC, Mattioli S, Grassetto G, Al-Nahhas A, Franchi R, Fanti S (2009) 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 30:281–286
Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, Bal C (2011) Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 197:1221–1228
Krausz Y, Freedman N, Rubinstein R et al (2011) 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 13:583–593
Naswa N, Sharma P, Soundararajan R, Karunanithi S, Nazar AH, Kumar R, Malhotra A, Bal C (2013) Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging 38:552–560
Ambrosini V, Campana D, Tomassetti P, Fanti S (2012) 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 39(Suppl 1):S52–S60
Poeppel TD, Binse I, Petersenn S et al (2011) 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 52:1864–1870
Putzer D, Kroiss A, Waitz D et al (2013) Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging 40:364–372
Demirci E, Ocak M, Kabasakal L et al (2013) Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Nucl Med Commun 34:727–732
Pfeifer A, Knigge U, Mortensen J et al (2012) Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 53:1207–1215
Pfeifer A, Johnbeck CB, Knigge U et al (2013) Clinical PET imaging of neuroendocrine tumors using 64Cu-DOTA-Tyr3-octreotate. J Nucl Med 54:1854
Putzer D, Gabriel M, Kendler D et al (2010) Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 54:68–75
Orlefors H, Sundin A, Ahlström H et al (1998) Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 16:2534–2541
Orlefors H, Sundin A, Garske U et al (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90:3392–3400
Koopmans KP, Neels OC, Kema IP et al (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26:1489–1495
Gutte H, Hansen AE, Henriksen ST, Johannesen HH et al (2015) Simultaneous hyperpolarized 13C-pyruvate MRI and 18F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. Am J Nucl Med Mol Imaging 5:38–45
Binderup T, Knigge U, Loft A et al (2010) 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16:978–985
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kjaer, A. (2015). Nuclear Medicine Imaging in Neuroendocrine Tumors. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-45215-8_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45214-1
Online ISBN: 978-3-662-45215-8
eBook Packages: MedicineMedicine (R0)